These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38054226)

  • 1. Prognostic model for assessing the human glioma cell malignancy grade based on MDM2, MELK, SOX2, CDK4, DR5 and OCT4 gene expression.
    Tyagunova EE; Drozd SF; Kalennik OV; Samoylenkova NS; Savchenko EA; Danilov GV; Pavlova GV
    Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):43-51. PubMed ID: 38054226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
    Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
    Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-time polymerase chain reaction analysis of MDM2 and CDK4 expression using total RNA from core-needle biopsies is useful for diagnosing adipocytic tumors.
    Sasaki T; Ogose A; Kawashima H; Hotta T; Hatano H; Ariizumi T; Umezu H; Ohashi R; Tohyama T; Tanabe N; Endo N
    BMC Cancer; 2014 Jun; 14():468. PubMed ID: 24965044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas.
    Guo Y; Liu S; Wang P; Zhao S; Wang F; Bing L; Zhang Y; Ling EA; Gao J; Hao A
    Histopathology; 2011 Oct; 59(4):763-75. PubMed ID: 22014056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells].
    Yan ZY; Sun XC
    Zhonghua Bing Li Xue Za Zhi; 2018 Apr; 47(4):284-290. PubMed ID: 29690669
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
    Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
    Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
    Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
    Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells.
    Ren L; Deng B; Saloura V; Park JH; Nakamura Y
    Oncol Rep; 2019 Apr; 41(4):2540-2548. PubMed ID: 30720113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner.
    Gu C; Banasavadi-Siddegowda YK; Joshi K; Nakamura Y; Kurt H; Gupta S; Nakano I
    Stem Cells; 2013 May; 31(5):870-81. PubMed ID: 23339114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR.
    Sirvent N; Coindre JM; Maire G; Hostein I; Keslair F; Guillou L; Ranchere-Vince D; Terrier P; Pedeutour F
    Am J Surg Pathol; 2007 Oct; 31(10):1476-89. PubMed ID: 17895748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
    Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
    Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells.
    Oppel F; Müller N; Schackert G; Hendruschk S; Martin D; Geiger KD; Temme A
    Mol Cancer; 2011 Nov; 10():137. PubMed ID: 22070920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
    Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
    Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.
    Schrage YM; Lam S; Jochemsen AG; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
    J Cell Mol Med; 2009 Sep; 13(9A):2843-52. PubMed ID: 18624751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
    Mejia-Guerrero S; Quejada M; Gokgoz N; Gill M; Parkes RK; Wunder JS; Andrulis IL
    Genes Chromosomes Cancer; 2010 Jun; 49(6):518-25. PubMed ID: 20196171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
    Kim YJ; Kim M; Park HK; Yu DB; Jung K; Song K; Choi YL
    Lab Invest; 2019 Sep; 99(9):1309-1320. PubMed ID: 31160689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential patterns of NOTCH1-4 receptor expression are markers of glioma cell differentiation.
    Dell'albani P; Rodolico M; Pellitteri R; Tricarichi E; Torrisi SA; D'Antoni S; Zappia M; Albanese V; Caltabiano R; Platania N; Aronica E; Catania MV
    Neuro Oncol; 2014 Jan; 16(2):204-16. PubMed ID: 24305720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioma SOX2 expression decreased after adjuvant therapy.
    Yu W; Ren X; Hu C; Tan Y; Shui Y; Chen Z; Zhang L; Peng J; Wei Q
    BMC Cancer; 2019 Nov; 19(1):1087. PubMed ID: 31718604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of long non-coding RNA PCAT19 inhibits glioma cell proliferation and invasion, and increases cell apoptosis through regulation of MELK targeted by miR-142-5p.
    Xie YH; Hu J
    Genes Genomics; 2020 Nov; 42(11):1299-1310. PubMed ID: 32980991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-181b sensitizes glioma cells to teniposide by targeting MDM2.
    Sun YC; Wang J; Guo CC; Sai K; Wang J; Chen FR; Yang QY; Chen YS; Wang J; To TS; Zhang ZP; Mu YG; Chen ZP
    BMC Cancer; 2014 Aug; 14():611. PubMed ID: 25151861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.